Skip to content
Screener

Atrium Therapeutics RNA Q2 2026 earnings

Reported August 13, 2026 · After market close

Revenue$3.0MBeat by $2.3M
EPS-$1.18Beat by $0.24
Revenue estimate$666.7K
EPS estimate-$1.42

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$15.0M
EPS estimate-$0.87

Versus estimates

Revenue

Q2 2026$3.0MBeat by $2.3M
Q1 2026$19.6MBeat by $17.6MQ4 2025$859.0KMiss by $1.3M

Diluted EPS

Q2 2026-$1.18Beat by $0.24
Q1 2026-$0.97Beat by $0.08Q4 2025-$1.70Miss by $0.46

FAQ

When did Atrium Therapeutics report Q2 2026 earnings?
Atrium Therapeutics (RNA) reported Q2 2026 earnings on August 13, 2026 after market close.
What were Atrium Therapeutics's Q2 2026 revenue and EPS?
Atrium Therapeutics reported revenue of $3.0M and eps of $-1.18 for Q2 2026.
Did Atrium Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $666.7K by $2.3M. EPS beat the consensus estimate of $-1.42 by $0.24.
Where can I find Atrium Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-349482) and the 10-Q periodic report (0001193125-26-349488) directly on SEC EDGAR. The filing index links above go to sec.gov.